Category Archives: Cancer and neoplasms

Abstract Background and objectives Various cross-sectional studies have observed an association between high circulating concentrations of the adipokine chemerin and an unfavorable metabolic profile. However, the prognostic value of chemerin for the risk of associated diseases and mortality was examined only in a few studies mostly using small and highly selected patient populations. We aimed […]

Specialty

Allogeneic CAR T-Cell Therapy CB-010 Demonstrates Potential in Phase 1 Relapsed/Refractory Non-Hodgkin Lymphoma Trial In the phase 1 ANTLER trial (NCT04637763), CB-010, an allogeneic CAR T-cell therapy, led to antitumor activity in most patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Among 16 patients treated in dose escalation, all of whom had received at least 2 prior lines […]

Specialty

Specialty

Introduction Nasopharyngeal carcinoma (NPC) is an insidious cancer of the head and neck, with the most frequent occurrence in East and South Asia, commonly arising in the pharyngeal recess.1 Worldwide, about 133,000 newly diagnosed cases of NPC and 80,000 deaths occur annually from the latest statistical data in 2020.2 Radiotherapy (RT) with or without chemoradiotherapy […]

Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:401–10. Article  PubMed  Google Scholar  Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602. Article  PubMed  Google Scholar  Mishra S, Kass DA. Cellular and molecular pathobiology […]

Key Points Question  What are the patterns of anticoagulant utilization and the anticoagulants associated with the lowest risk for venous thromboembolism (VTE) recurrence in patients with cancer in a clinical setting? Findings  In this comparative effectiveness study with 5100 adult patients, twice as many patients were prescribed direct oral anticoagulants (DOACs) as other classes, and […]

Ann M. Gillenwater, MD ASP-1929, an antibody-dye conjugate, induced responses when used in combination with pembrolizumab (Keytruda) to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), according to preliminary data from the phase 1b/2 ASP-1929-181 trial (NCT04305795).1 Findings presented at the American Head and Neck Society’s (AHNS) 11th International Conference on […]

Investigators have identified significant differences between the tumors of patients with high-grade serous ovarian cancer (HGSC) who have short survival periods and those of patients with longer-term survival. The findings, which were reported in the journal Communications Biology, could help clinicians better clarify patients’ likely disease courses and also help scientists identify new drug targets, […]